Compare Enact Holdings Inc (ACT) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs AstraZeneca plc — how do they compare? Enact Holdings Inc trades at $49.07 (market cap $6.67B), while AstraZeneca plc trades at $158.1 (market cap $250.84B). The key difference: AstraZeneca plc is far larger — about 37.6× Enact Holdings Inc's market cap, and Enact Holdings Inc pays the higher dividend (1.98%). Which is the better fit depends on your goals.
| ACT | AZN | |
|---|---|---|
Market Cap | $6.67B | $250.84B |
Sector | Technology | Health |
52-Week High | $49.12 | $209.48 |
52-Week Low | $34.93 | $147.06 |
Enterprise Value | $6.96B | $278.12B |
Dividend Yield | 1.98% | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $48.96, up 0.6% today, near the consensus price target of $49.00. The stock shows strong fundamentals with a P/E of 10.23 and robust net income margin of 54.51%. Recent Q2 2026 earnings beat expectations at $1.26 per share. Technical indicators signal a bullish trend with moving averages supporting upside momentum. The company maintains consistent dividend payments and positive revenue growth projections.
Outlook remains positive with analyst consensus favoring buy/hold ratings and price targets suggesting limited upside. Key risks include execution challenges and market volatility. Earnings growth and dividend consistency provide support, but investors should monitor competitive pressures and macroeconomic factors that could impact performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
